Genomics BioSci & Tech. Co.Ltd. (4195) fair value: what the stock is really worth
As of Jul 9, 2026: fair value of Genomics BioSci & Tech. Co.Ltd. TWD 4.26, price TWD 17.85, upside -76.1%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Genomics BioSci & Tech. Co.Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; clinical testing services, such as reproductive health and cancer testing services; and contract development and manufacturing services.
Show more
Genomics BioSci & Tech. Co.,Ltd. operates as a genomic company in Taiwan. The company offers sequencing, synthesis, genomic, proteomic, and agency and sales services; clinical testing services, such as reproductive health and cancer testing services; and contract development and manufacturing services. The company was founded in 2001 and is based in New Taipei City, Taiwan.
Stock analysis
Genomics BioSci & Tech. Co.Ltd. (4195) currently trades at 17.85 TWD, while our model-based Fair Value estimate is 4.26 TWD, 76.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: 3.18 TWD (bear) to 6.35 TWD (bull), the price of 17.85 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Genomics BioSci & Tech. Co.Ltd. reported revenue of 708M TWD in FY2025 versus 390M TWD in FY2021, a compound +16.1%/yr. Reported net income was −39.4M TWD in FY2025.
Key figures
Market cap 2.4B TWD (≈ $74.1M) · P/S ratio 3.33 · EPS (TTM) −0.5400 TWD · Net margin −5.6% · Return on equity −11.1% · Return on assets (EBIT) −4.4% · Operating margin −6.1% · Revenue (TTM) 708M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).
What moves the price
The share trades about 50% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −76%, 4195 screens richer than that median.
Fair Value models
Bear 3.18 TWDFair Value 4.26 TWDBull 6.35 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
0.4% (2020) → −10.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Genomics BioSci & Tech. Co.Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score44 · Above median
Fair Value upside−76.1% · Bottom 25%
Profitability
Return on assets−3.8% · Above median
Net margin (TTM)−5.6% · Below median
Operating margin (TTM)−6.1% · Below median
Growth and dividend
Revenue growth42.5% · Top 25%
Balance sheet
Debt / equity0.59× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.14× · Cheapest 25%
P/S (TTM)0.10× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)70· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genomics BioSci & Tech. Co.Ltd. (4195) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 4.26 TWD versus the last price from Jul 9, 2026 of 17.85 TWD, about −76% upside (overvalued).
What is the fair value of 4195?
Our model-based fair value for Genomics BioSci & Tech. Co.Ltd. is 4.26 TWD (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 9, 2026): 17.85 TWD.
What is the quality score of 4195?
Genomics BioSci & Tech. Co.Ltd. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genomics BioSci & Tech. Co.Ltd. (4195)?
Our model-based price target is the fair value of 4.26 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 3.18 TWD, optimistic scenario 6.35 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Genomics BioSci & Tech. Co.Ltd. stock forecast for 2026?
Our models put fair value at 4.26 TWD, about −76% upside versus the last price from Jul 9, 2026 of 17.85 TWD (overvalued). Cautious scenario 3.18 TWD, optimistic scenario 6.35 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Genomics BioSci & Tech. Co.Ltd. (4195)?
Genomics BioSci & Tech. Co.Ltd. reported trailing-twelve-month revenue of about 708M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Genomics BioSci & Tech. Co.Ltd. (4195)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genomics BioSci & Tech. Co.Ltd. it is 4.26 TWD per share (as of Sep 24, 2026), against a price of 17.85 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Genomics BioSci & Tech. Co.Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4195 trades above its calculated fair value: price 17.85 TWD, fair value 4.26 TWD, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4195?
No. The price is what the market pays today (17.85 TWD); the fair value is what the company's own numbers justify (4.26 TWD). For Genomics BioSci & Tech. Co.Ltd. the two are 13.59 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Genomics BioSci & Tech. Co.Ltd. worth?
The market values Genomics BioSci & Tech. Co.Ltd. at about 2.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 17.85 TWD; our models calculate a fair value of 4.26 TWD per share.
What do the bullish and bearish scenarios say about 4195?
Our models span a range for Genomics BioSci & Tech. Co.Ltd.: cautious scenario 3.18 TWD, base 4.26 TWD, optimistic 6.35 TWD per share (as of Sep 24, 2026, price 17.85 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genomics BioSci & Tech. Co.Ltd. (4195)?
Balance-sheet figures for Genomics BioSci & Tech. Co.Ltd. (as of Sep 24, 2026): return on equity −11.1%, debt of 0.59 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 4195 from its 52-week high?
Genomics BioSci & Tech. Co.Ltd. trades at 17.85 TWD, about 50% below its 52-week high of 35.40 TWD and 17% above the low of 15.20 TWD (as of Jul 9, 2026). Distance from the high says nothing about value: that is what the fair value of 4.26 TWD is for.
Which stocks are comparable to Genomics BioSci & Tech. Co.Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genomics BioSci & Tech. Co.Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 17.85 TWD, calculated fair value 4.26 TWD (−76%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4195 calculated?
We run Genomics BioSci & Tech. Co.Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.26 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Genomics BioSci & Tech. Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genomics BioSci & Tech. Co.Ltd. (4195)?
The latest price we hold is from Jul 9, 2026 and stands at 17.85 TWD. Our model-based fair value is 4.26 TWD, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genomics BioSci & Tech. Co.Ltd. right now?
The price sits above even our optimistic bull case (6.35 TWD). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.18 TWD to 6.35 TWD) leaves room in how you read the outcome.
Key figures of Genomics BioSci & Tech. Co.Ltd.
How large is the market capitalisation of Genomics BioSci & Tech. Co.Ltd. (4195)?
The market capitalisation of Genomics BioSci & Tech. Co.Ltd. is 2.4B TWD (≈ $74.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genomics BioSci & Tech. Co.Ltd. (4195)?
The price-to-sales ratio of Genomics BioSci & Tech. Co.Ltd. is 3.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genomics BioSci & Tech. Co.Ltd. (4195)?
Earnings per share at Genomics BioSci & Tech. Co.Ltd. are −0.5400 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genomics BioSci & Tech. Co.Ltd. (4195)?
The net margin of Genomics BioSci & Tech. Co.Ltd. is −5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genomics BioSci & Tech. Co.Ltd. (4195)?
The return on equity (ROE) of Genomics BioSci & Tech. Co.Ltd. is −11.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genomics BioSci & Tech. Co.Ltd. (4195)?
On an EBIT basis the return on assets of Genomics BioSci & Tech. Co.Ltd. is −4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genomics BioSci & Tech. Co.Ltd. (4195)?
The operating margin of Genomics BioSci & Tech. Co.Ltd. is −6.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genomics BioSci & Tech. Co.Ltd. (4195)?
Revenue at Genomics BioSci & Tech. Co.Ltd. is growing +42.5% versus a year earlier (3y avg +19.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genomics BioSci & Tech. Co.Ltd. (4195) generate?
The free cash flow of Genomics BioSci & Tech. Co.Ltd. is −172M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Genomics BioSci & Tech. Co.Ltd. (4195) carry?
The net debt of Genomics BioSci & Tech. Co.Ltd. is 474M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genomics BioSci & Tech. Co.Ltd. in the live analysis
One click puts Genomics BioSci & Tech. Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
